

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/18240 A2

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/CA00/01043

(22) International Filing Date:
8 September 2000 (08.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,282,062 8 September 1999 (08.09.1999) CA
60/160,618 20 October 1999 (20.10.1999) US
2,303,504 10 April 2000 (10.04.2000) CA

(71) Applicant (for all designated States except US): THE
UNIVERSITY OF BRITISH COLUMBIA [CA/CA];

University-Industry Liaison Office, IRC Building, Room
331, 2194 Health Sciences Mall, Vancouver, British
Columbia V6T 1Z3 (CA).


(72) Inventors; and

(75) Inventors/Applicants (for US only): KEOWN, Paul
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). KHANI-HANJANI, Abbas
[CA/CA]; Immunology Laboratory, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British
Columbia V5Z 1M9 (CA). HOAR, David [CA/CA];
Immunology Laboratory, Vancouver General Hospital,
855 West 12th Avenue, Vancouver, British Columbia V5Z
1M9 (CA).

(74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar,
Box 11560, Vancouver Centre, 650 West Georgia Street,
Suite 2200, Vancouver, British Columbia V6B 4N8 (CA).

[Continued on next page]

(54) Title: DIAGNOSTIC AND THERAPEUTIC METHODS IN AUTOIMMUNE DISEASE



(57) Abstract: In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene. The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon, gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 bp allele and the 122 bp allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. The invention may also comprise testing a patient for a polymorphism is an HLA protein (or gene), such as the HLA-DRB1 protein.